India, Aug. 20 -- Journey Medical Corporation (DERM), a commercial-stage pharmaceutical company focused on dermatological treatments, reported financial results for the second quarter ended June 30, 2026, highlighting continued commercial momentum for Emrosi and progress toward profitability.
Company Profile
U.S.-based Journey Medical develops, sells and markets FDA-approved prescription pharmaceutical products for dermatological conditions. Its portfolio includes Emrosi (DFD-29), an oral treatment for patients with rosacea.
Q2 FY26 Highlights
For the second quarter, Journey Medical reported total revenue of $18.5 million, up 23% from $15.0 million in Q2 2025. Growth was primarily driven by continued demand for Emrosi, which generated $...